Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

• Published in: Xenobiotica Vol. 45; no. 1; pp. 45 - 59
• Main Authors: Johnson, Theodore R., Tan, Weiwei, Goulet, Lance, Smith, Evan B., Yamazaki, Shinji, Walker, Gregory S., O'Gorman, Melissa T., Bedarida, Gabriella, Zou, Helen Y., Christensen, James G., Nguyen, Leslie N., Shen, Zhongzhou, Dalvie, Deepak, Bello, Akintunde, Smith, Bill J.
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01.01.2015; Informa Healthcare
• Subjects: Administration, Oral; Adult; Carbon Radioisotopes; Crizotinib; excretion; Feces - chemistry; Healthy Volunteers; human; Humans; Male; metabolism; Middle Aged; oncology; pharmacokinetics; Protein Kinase Inhibitors - analysis; Protein Kinase Inhibitors - metabolism; Protein Kinase Inhibitors - pharmacokinetics; Pyrazoles - analysis; Pyrazoles - metabolism; Pyrazoles - pharmacokinetics; Pyridines - analysis; Pyridines - metabolism; Pyridines - pharmacokinetics; Crizotinib; pharmacokinetics; metabolism; excretion; human; oncology

Abstract 1. Crizotinib (XALKORI®), an oral inhibitor of anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition factor kinase (c-Met), is currently approved for the treatment of patients with non-small cell lung cancer that is ALK-positive. 2. The metabolism, excretion and pharmacokin...